Recent Research Analysts’ Ratings Changes for Neos Therapeutics (NEOS)

Neos Therapeutics (NASDAQ: NEOS) recently received a number of ratings updates from brokerages and research firms:

  • 8/12/2019 – Neos Therapeutics had its price target lowered by analysts at BMO Capital Markets from $4.00 to $3.00. They now have a “market perform” rating on the stock.
  • 8/10/2019 – Neos Therapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Neos Therapeutics, Inc. is engaged in developing, manufacturing and commercializing products for the treatment of attention deficit hyperactivity disorder using drug delivery technologies. Its product candidates include NT-0102 methylphenidate XR orally disintegrating tablet for the treatment of ADHD; NT-0202 amphetamine XR orally disintegrating tablet for the treatment of ADHD; NT-0201 amphetamine XR liquid suspension for the treatment of ADHD and Generic Tussionex, which are in different clinical development stage. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas. “
  • 8/8/2019 – Neos Therapeutics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $1.25 price target on the stock. According to Zacks, “Neos Therapeutics, Inc. is engaged in developing, manufacturing and commercializing products for the treatment of attention deficit hyperactivity disorder using drug delivery technologies. Its product candidates include NT-0102 methylphenidate XR orally disintegrating tablet for the treatment of ADHD; NT-0202 amphetamine XR orally disintegrating tablet for the treatment of ADHD; NT-0201 amphetamine XR liquid suspension for the treatment of ADHD and Generic Tussionex, which are in different clinical development stage. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas. “
  • 8/1/2019 – Neos Therapeutics was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 7/26/2019 – Neos Therapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Neos Therapeutics, Inc. is engaged in developing, manufacturing and commercializing products for the treatment of attention deficit hyperactivity disorder using drug delivery technologies. Its product candidates include NT-0102 methylphenidate XR orally disintegrating tablet for the treatment of ADHD; NT-0202 amphetamine XR orally disintegrating tablet for the treatment of ADHD; NT-0201 amphetamine XR liquid suspension for the treatment of ADHD and Generic Tussionex, which are in different clinical development stage. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas. “
  • 7/25/2019 – Neos Therapeutics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $1.50 price target on the stock. According to Zacks, “Neos Therapeutics, Inc. is engaged in developing, manufacturing and commercializing products for the treatment of attention deficit hyperactivity disorder using drug delivery technologies. Its product candidates include NT-0102 methylphenidate XR orally disintegrating tablet for the treatment of ADHD; NT-0202 amphetamine XR orally disintegrating tablet for the treatment of ADHD; NT-0201 amphetamine XR liquid suspension for the treatment of ADHD and Generic Tussionex, which are in different clinical development stage. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas. “
  • 7/19/2019 – Neos Therapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Neos Therapeutics, Inc. is engaged in developing, manufacturing and commercializing products for the treatment of attention deficit hyperactivity disorder using drug delivery technologies. Its product candidates include NT-0102 methylphenidate XR orally disintegrating tablet for the treatment of ADHD; NT-0202 amphetamine XR orally disintegrating tablet for the treatment of ADHD; NT-0201 amphetamine XR liquid suspension for the treatment of ADHD and Generic Tussionex, which are in different clinical development stage. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas. “
  • 7/18/2019 – Neos Therapeutics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $1.50 price target on the stock. According to Zacks, “Neos Therapeutics, Inc. is engaged in developing, manufacturing and commercializing products for the treatment of attention deficit hyperactivity disorder using drug delivery technologies. Its product candidates include NT-0102 methylphenidate XR orally disintegrating tablet for the treatment of ADHD; NT-0202 amphetamine XR orally disintegrating tablet for the treatment of ADHD; NT-0201 amphetamine XR liquid suspension for the treatment of ADHD and Generic Tussionex, which are in different clinical development stage. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas. “
  • 7/11/2019 – Neos Therapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Neos Therapeutics, Inc. is engaged in developing, manufacturing and commercializing products for the treatment of attention deficit hyperactivity disorder using drug delivery technologies. Its product candidates include NT-0102 methylphenidate XR orally disintegrating tablet for the treatment of ADHD; NT-0202 amphetamine XR orally disintegrating tablet for the treatment of ADHD; NT-0201 amphetamine XR liquid suspension for the treatment of ADHD and Generic Tussionex, which are in different clinical development stage. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas. “

Shares of NEOS traded up $0.06 during trading hours on Thursday, hitting $1.76. The stock had a trading volume of 190,356 shares, compared to its average volume of 384,545. The company has a debt-to-equity ratio of 41.70, a current ratio of 1.49 and a quick ratio of 1.27. Neos Therapeutics Inc has a 12 month low of $1.13 and a 12 month high of $6.00. The company has a market cap of $87.53 million, a price-to-earnings ratio of -1.10 and a beta of 1.19. The firm has a fifty day moving average price of $1.41.

Neos Therapeutics (NASDAQ:NEOS) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.17) by $0.09. The company had revenue of $15.64 million for the quarter, compared to the consensus estimate of $16.70 million. As a group, analysts forecast that Neos Therapeutics Inc will post -0.65 EPS for the current fiscal year.

Several large investors have recently bought and sold shares of the stock. Virtu Financial LLC purchased a new stake in Neos Therapeutics during the first quarter valued at approximately $131,000. BlackRock Inc. grew its holdings in Neos Therapeutics by 28.8% during the 4th quarter. BlackRock Inc. now owns 2,733,411 shares of the company’s stock worth $4,510,000 after acquiring an additional 610,660 shares in the last quarter. BNP Paribas Arbitrage SA boosted its holdings in shares of Neos Therapeutics by 1,749.5% in the 1st quarter. BNP Paribas Arbitrage SA now owns 10,098 shares of the company’s stock valued at $26,000 after buying an additional 9,552 shares during the period. Jane Street Group LLC acquired a new position in shares of Neos Therapeutics in the 4th quarter valued at about $62,000. Finally, Alambic Investment Management L.P. acquired a new position in shares of Neos Therapeutics in the 1st quarter valued at about $32,000. Institutional investors own 54.88% of the company’s stock.

Neos Therapeutics, Inc, a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms.

Featured Article: The primary rules of Elliott Wave theory

Receive News & Ratings for Neos Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.